About Volta
Non Dispersed Electrocardiograms
Dispersed Electrocardiograms


1
dispersion location
Multipolar electrogram abnormality associated with the perpetuation of atrial fibrillation. Red: highly dispersed electrograms, Orange: dispersed electrograms, Blue: non-dispersed electrograms.
2
mapping catheter
Steerable, multipolar electrode catheter. Allows for the recording of the local electrical activity.
3
reference cycle length
Atrial cycle length estimated from recordings obtained with the coronary sinus catheter.
4
mapping cycle length
Local cycle length estimated from real-time recordings obtained with the mapping catheter.





1
dispersion location
Multipolar electrogram abnormality associated with the perpetuation of atrial fibrillation. Red: highly dispersed electrograms, Orange: dispersed electrograms, Blue: non-dispersed electrograms.
2
mapping catheter
Steerable, multipolar electrode catheter. Allows for the recording of the local electrical activity.
3
reference cycle length
Atrial cycle length estimated from recordings obtained with the coronary sinus catheter.
4
mapping cycle length
Local cycle length estimated from real-time recordings obtained with the mapping catheter.
Compliance
Patient privacy: All data collected is anonymized or pseudonymized in compliance with Data Protection regulations. Notably, data undergoes a state-of-the-art encryption (dual process, dual keys). Our policy meets the highest standards of data protection.
CE marked & FDA cleared: Volta’s VX1 software solution is the first AI-based solution in the interventional cardiology space to have obtained FDA clearance and CE marking.
Technology
Real time analysis: VX1 provides state-of-the-art analysis in real-time, ensuring optimal usability.
Precision: its integration allows for high density mapping in both atria.
Intellectual Property: Volta’s technology is protected internationally with multiple patents.
Data Driven: VX1 algorithm has been trained on large, carefully curated databases. Our goal is to mimic the expertise of trained physicians and reduce inter-operator variability in identifying specific abnormal electrograms.
Compatibility
Most multipolar mapping catheters
Two EP recording systems
Most 3D navigation systems
VX1. vs. Trained Expert Cardiac Electrophysiologists
Conclusions
SOURCE: HRS 2020 Imagineer Tech Showcase.
-
The clinical significance of utilizing the VX1 software to help identify areas with intra-cardiac atrial electrograms exhibiting spatiotemporal dispersion
for catheter ablation of atrial arrhythmias, such as atrial fibrillation, has not been established by clinical investigations.

Our team
Management

Théophile Mohr Durdez
CEO, co-founder
+

Théophile Mohr Durdez
CEO, co-founder
Théophile grew up in France, Germany and Austria. Since his young age, he wanted to help his fellow humans with technology. Latter on, he studied at Ecole polytechnique (Paris), where he fell in love with Statistics, Machine and Deep Learning. There, he obtained a double degree with the Business School HEC (Paris).
His first accomplishment was to create a wheelchair controlled via eye-tracking for SLA disabled people. He then helped in solving complex geophysics with the use of differential equations.
In 2016, he co-founded Volta, where he was the passionate architect and inventor of Volta’s algorithms. In 2017, Théophile received the Research Award from Ecole polytechnique for the algorithms that he developed at Volta.
Théophile is hiring and leading a team of top-talents to drive Volta towards success by making a difference for operators and patients.

Julien Seitz
President, co-founder
+

Julien Seitz
President, co-founder
Julien is the acting Chief of the cardiac electrophysiology section at Saint Joseph Hospital (Marseille, France).
St-Joseph hospital is one of the three highest-volume ablation center in the country. This gave him many opportunities to think deep about what interventional cardiologists need most. Julien is well-known for his contributions to the field of electrogram-based ablation. He has published plenty of manuscripts in high-impact cardiology journals. He is a regular guest speaker, chairman at major conferences.
Since he started as an interventional cardiologist, Julien has been obsessed with making accessible any complex ablation approach to large numbers of colleague physicians. He started with conceptualizing multipolar-electrogram visual interpretation into a series of simple steps.
Since Volta was created, he used his in-depth experience to help design AI algorithms that provide simple but powerful cues to cardiologists.

Jérome Kalifa
Chairman, CMO, co-founder
+

Jérome Kalifa
Chairman, CMO, co-founder
Both basic scientist and clinical electrophysiologist, Jérôme is based in the USA and currently Faculty at Brown University, Rhode Island, USA.
Jérôme dedicated about two decades to translational and clinical research in cardiac electrophysiology.
He is a seasoned speaker, chairman and reviewer for cardiology journals and conferences. His research effort has focused on understanding atrial fibrillation mechanisms as they pertain to cardiac interventions.
His background in cardiac mapping, imaging, database management and catheter technologies helped us design Volta’s algorithms.
Jérôme’s knowledge of the US clinical landscape is helping Volta address the needs of US users.

Clément Bars
VP, co-founder
+

Clément Bars
VP, co-founder
Clément has devoted his career to refining his understanding of procedural work flows in the field of cardiovascular electrophysiology.
Clement has become a well-known expert at simplifying work flows, specifically as they pertain to atrial fibrillation catheter ablation. His many contributions to the field of ablation could be summarized as “Do what you understand well, but keep it simple”.
He is regularly invited as a guest speaker or as a proctor in major hospitals in Europe, USA and Asia.
At Volta, he oversees the clinical evaluation of Volta’s algorithms. With more than 40 cardiac electrophysiologists visiting us last year alone, Clément has formed a large network of interventional cardiologists that cannot wait to try Volta’s algorithms.

Paola Milpied
VP Clinical & Regulatory Affairs
+

Paola Milpied
VP Clinical & Regulatory Affairs
Paola is a former engineer and data scientist who holds a PhD in signal processing and machine learning applied to Cardiology. She has 13+ years of experience in medical device companies in France and in the US where she held several roles in clinical research and regulatory affairs in the cardiovascular field.
At Volta, Paola leads the clinical, quality and regulatory affairs department with an ambitious clinical program as well as major regulatory challenges.

Laurent Launay
VP Engineering
+

Laurent Launay
VP Engineering
Ph.D. in Computer Science
24+ years of experience in GE Healthcare and IRT b-com
Worked as Senior Manager for 3D applications, workstations applications and platforms

John Slump
CFO
+

John Slump
CFO
Founder/CFO of multiple med-tech companies including FARAPULSE acquired by Boston Scientific Experienced medical devices & health tech operator
Raised >$100M of total startup financing and returned >$500M of exit value to shareholders with an attractive ROI

Jeff Martin
VP of Global Marketing
+

Jeff Martin
VP of Global Marketing
20 years of experience in med device marketing.
Previously Marketing Director at Acutus; Group Product Director at Biosense Webster.
Highly effective in development and execution of global strategic marketing/field team plans.

El Makki Voundy
Full-Stack Developer

Fabienne Pouplier
DPO

Mohsen Shah
Director of US Operations

Daniel Guerrero
US Clinical Operations Manager

Didier Villevalois
Full-Stack Developer

Philippe Tartaise
Software Engineering Manager

Sabrina Siame
Clinical Research Assistant

Aman
Business Analyst

Loren Siry
HR Manager

Dinara Veshchezerova
Data Scientist

Mélanie Reist
Field Technical Engineer

Meryem Serdi
Field Technical Engineer

Maxime Basset
Field Technical Engineer

Yoann Dutil
QMS Compliance Manager

Audrey Balzano
Executive Assistant

Thomas Boudou
Data Scientist

Camille Schmisser
Clinical & Regulatory Affairs Specialist

Idriss Lopes Sanches
Full Stack Developer

Aurélien Rosiau
Full-Stack Developer

Vianney Guesdon-Vennerie
Front-End Developer

Denis Hansjacob
COO
+

Denis Hansjacob
COO
After more than 30 years as a high-level executive in the Biomedical Device Industry, Denis decided to join Volta to be part of the next wave of technology designed for the operating room.
Denis has been Managing Director of St. Jude Medical France and Vice-President for Northern Europe, where he led commercial operations. He has a unique understanding of marketing, sales and reimbursement mechanisms. Denis is helping Volta’s products spread quickly in Europe and the USA.
Also, Denis is shaping the future of biomedical devices revenue model. Denis is the proponent that AI is the best solution to cure more patients from AF in the best cost efficient way.

Anthony Appetiti
Head of Sales EU

Rebecca Sircoulomb
Head of product
Investors & Partners
Press releases
Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation
Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation
- First randomized controlled clinical trial to evaluate VX1-guided ablation compared to conventional anatomical ablation approaches to treat persistent atrial fibrillation
- International, multi-center trial involving 26 sites, 374 patients is expected to report results in 2024
Marseille (France), February 2, 2023 – Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced the completion of patient enrollment in the randomized controlled clinical trial, TAILORED-AF, evaluating VX1-guided ablation compared to a ‘standard of care’ anatomical ablation approach.
The company’s lead product, VX1, is the first commercially available AI decision-support software to help guide physicians with identification and real-time annotation of unique abnormalities (so called “dispersed electrograms“) on 3D anatomical and electrical maps of the heart. This technology ultimately may lead to optimized catheter-ablation procedures for complex arrhythmias, including persistent AF.
“Atrial fibrillation is the most common heart rhythm disturbance in adults and the need for more precise therapies is significant,” said Professor Isabel Deisenhofer, MD, of German Heart Center in Munich, Germany and primary investigator for the trial. “While catheter ablation is well-established as an important treatment for AF, a more consistent standard of care is needed for its more progressed disease state, known as persistent AF. VX-1 has the potential to meet that need by assisting electrophysiologists in delivering successful outcomes with each patient ablation.”
The TAILORED-AF clinical trial is an international, multicenter, randomized controlled study designed to confirm the clinical significance of VX1 and lay the groundwork for establishing VX1 as a new standard of care for persistent AF ablation. The primary endpoint is freedom from documented AF episodes lasting longer than 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure. Secondary endpoints include absence of AF and/or atrial tachycardia (AT) episodes after a 12-month period, following one or more procedures, as well as safety.
“We are committed to helping physicians use EGM-assessment software to guide ablation and providing another clinical tool to support the best possible outcomes for patients,” said Theophile Mohr-Durdez, Volta Medical CEO and co-founder. “We are excited to complete patient enrollment in this 26-site controlled trial and continue studying our VX1 platform, and look forward to reporting the results in 2024 to provide electrophysiologists more essential, life-changing care options to patients.”
About the TAILORED-AF Trial
TAILORED-AF is an international, multicenter trial designed to determine if a tailored VX1 AI software-guided ablation strategy targeting areas of spatiotemporal dispersion in combination with pulmonary vein isolation (PVI) is superior to a conventional anatomical ablation strategy targeting PVI alone for the treatment of persistent AF. The primary endpoint of the study is the absence of documented AF episodes > 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure. Secondary endpoints include absence of AF and/or atrial tachycardia (AT) episodes after a 12-month period, following one or more procedures, as well as safety. Volta Medical expects results from the TAILORED-AF trial in 2024.
About Volta Medical
Volta Medical is a health technology company developing artificial intelligence software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Founded by three physicians and a data scientist in 2016 in Marseille, Volta’s overarching goal is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection. The company’s first product, VX1, is a digital AI companion device and algorithm to assist cardiologists with real-time identification of specific abnormal electrograms (EGMs), known as dispersed EGMs. For more information, visit the company’s website at www.volta-medical.com.
Media Contact
Jeff Martin, VP of Global Marketing
Volta Medical
jeffrey.martin@volta-medical.com
U.S. Media Contact
Glenn Silver
Finn Partners
glenn.silver@finnpartners.com
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
- New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence (AI) Decision-Support Software in improving catheter ablation for complex cardiac arrhythmias
- Medical device executive John Slump joins as Chief Financial Officer
Marseille (France), January 5, 2023 – Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced €36 million in new Series B funding, bringing the total capital raised to over €70 million.
The funding round was led by U.S.-based Vensana Capital with co-investment from Lightstone Ventures and existing investor Gilde Healthcare. The funding will help accelerate new product development, support additional clinical trials, prepare for full-scale US commercialization, and pursue further regulatory approvals. The company’s lead product, VOLTA VX1, is the first commercially available AI decision-support software to help guide physicians with identification and real-time annotation of unique abnormalities (so called “dispersed electrograms“) on 3D anatomical and electrical maps of the heart. This technology ultimately may lead to optimized catheter-ablation procedures for complex arrhythmias, including persistent AF.
“There is a critical need to improve precision and consistency in cardiac ablation procedures for patients with persistent AF.” said Theophile Mohr Durdez, Volta Medical CEO and co-founder. “With half of these patients requiring repeat treatments, clinicians need tools that enable them to better understand the disease and drastically improve patient outcomes. We believe VOLTA’s VX1 has the potential to do just that in a consistent, reproducible way. We are most grateful to the teams at Vensana, Lightstone, and Gilde for their support and confidence as we partner to further validate our products and expand access to it globally.”
“Volta Medical’s technology is designed to redefine how electrophysiologists make real-time decisions in pinpointing areas relevant to atrial fibrillation persistence,” said Justin Klein, MD, JD, co-founder and managing partner of Vensana Capital. “We applaud the team’s commitment to validating their products with an investment in multiple high quality clinical trials. We are confident that Volta’s innovative AI software will transform the effectiveness and efficiency of these challenging procedures.”
Volta Medical also is pleased to announce the appointment of experienced medical device executive, John Slump, as CFO of Volta Medical. A seasoned operator in the industry, John has a proven track record as a founder and CFO, leading multiple MedTech companies from concept through regulatory approvals, commercial growth, and strategic acquisitions. Most recently, he served as CFO of Surgical Innovation Associates, a rapidly growing medical device company in the reconstructive and plastic surgery market that was acquired by Integra LifeSciences. Prior to that, John co-founded FARAPULSE, a medical device company in electrophysiology pioneering novel pulsed field ablation technology that was acquired in 2021 by Boston Scientific. Previously, John served as CFO of Attune Medical, an emerging growth medical device company commercializing proprietary esophageal temperature management devices in electrophysiology and other surgical markets.
“I’m excited to join the Volta Medical team and am pleased with our ability to attract significant equity investment from both new and existing investors in an increasingly challenging fundraising climate,” John said. “VOLTA VX1 has the potential to make a major difference in the lives of millions of people with AF, and this Series B Financing will help to accelerate its development and adoption nationally and across the globe.”
About Volta Medical
Volta Medical is a health technology company developing artificial intelligence software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Founded by three physicians and a data scientist in 2016 in Marseille, Volta’s overarching goal is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection. The company’s first product, VX1, is a digital AI companion device and algorithm to assist cardiologists with real-time identification of specific abnormal electrograms (EGMs), known as dispersed EGMs. For more information, visit the company’s website at www.volta-medical.com.
About Vensana Capital
Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Launched in 2019, Vensana manages $550M in capital and is actively investing in development and commercial stage companies across the MedTech sector, including medical devices, diagnostics and data science, life science tools, digital health, and tech-enabled services. Vensana’s investment team has a history of successfully partnering with management teams behind industry-leading companies including Cameron Health, CardiAQ, Cartiva, CV Ingenuity, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical. Learn more at www.vensanacap.com.
About Lightstone Ventures
Lightstone Ventures is a global venture capital firm investing in biotech and MedTech companies pioneering big ideas poised to transform patient outcomes. Lightstone Ventures was founded in 2012 to empower visionary entrepreneurs with the resources and operational guidance necessary to bring their innovative therapeutics and technologies to the patients who need them most. Lightstone Ventures’ investment team has led deals resulting in 19 acquisitions and 20 initial public offerings over the last two decades. The firm has offices in Boston, Mass., Menlo Park, Calif., Dublin, Ireland and Singapore. For more information, visit www.lightstonevc.com.
About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor with two fund strategies: Venture&Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in fast growing, innovative companies active in (bio)pharmaceuticals, healthtech and medtech that are based in Europe and North America. For more information, please visit www.gildehealthcare.com.
Media Contact
Jeff Martin, VP of Global Marketing
Volta Medical
jeffrey.martin@volta-medical.com
U.S. Media Contact
Glenn Silver
Finn Partners
glenn.silver@finnpartners.com
Europe Media Contact
Julia Bittner
MC Services AG
julia.bittner@mc-services.eu
France Media Contact
Caroline Carmagnol
Alize RP
caroline@alizerp.com
Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication
Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication
• Volta VX1 decision support software reproduces expert-physician electrogram(EGM) analysis that can assist physicians in the real-time identification of specific abnormal electrograms in a persistent atrial fibrillation (AF) population
• After a one-year follow-up, patients demonstrated a high freedom from atrial fibrillation and from any atrial arrhythmia, 89% and 73% after an average of 1.3 procedures per patient, respectively
• VX1 allowed for robust center-to-center standardization of identification of abnormal electrograms, confirming reproducibility of results across 8 centers and 17 operators
• The Ev-AIFib study was an open-label single-arm uncontrolled study comparing the acute and long-term outcomes of 85 patients in persistent AF after ablation in regions exhibiting VX1-highlighted abnormal electrograms
• The ongoing Tailored-AF randomized controlled trial is designed to demonstrate clinical significance and compare the outcomes of VX1-guided ablation versus standard ablation
Marseille (France), 31 August 2022 – Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, today announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s successful Ev-AIFib-Proof-of-Concept-Study with VX1, an expertise-based AI software solution to assist operators in the real-time identification of specific abnormal electrograms (EGM) during atrial fibrillation (AF) procedures. The article titled “Artificial Intelligence Software Standardizes Electrogram-based Ablation Outcome for Persistent Atrial Fibrillation” is available at https://onlinelibrary.wiley.com/doi/abs/10.1111/jce.15657.
The study was the first large-scale clinical validation of a companion AI-based software solution that reproduces expert-physician electrogram (EGM) analysis and assists operators in the real-time identification of specific abnormal EGMs, known as dispersed EGMs, during ablation procedures in a persistent AF population. Results demonstrated that VX1 allowed for the building of standardized “Volta VX1 maps”, used as a reference for operators to conduct EGM-guided ablation. The standardization of the detection of abnormal EGMs facilitated a robust patient-to-patient and center-to-center uniformity in EGM-based ablation. No major differences between operator’s visual analysis and VX1 EGM maps were recorded, and there were no statistically significant differences between outcomes across the 8 study centers and 17 operators. Furthermore, after a one-year follow-up, patients demonstrated a high freedom from atrial fibrillation and from any atrial arrhythmia, 89% and 73% after an average of 1.3 procedures per patient, respectively. Also, notably there was acute AF termination of 88% for subjects in all centers.
“Catheter ablation is well-established as an important treatment for AF and is by far the most common cardiac ablation procedure performed worldwide. Due to the complexity of persistent AF, however, there is no uniform standard of care resulting in heterogenous approaches that yield mixed and often disappointing results associated with high recurrence rates”, said Jean-Paul Albenque, MD, Cardiac Electrophysiologist at the Clinique Pasteur, Toulouse, France, and co-author of the study. “Strategies using EGM assessment to guide ablation visually, rely heavily on the individual experience of the treating electrophysiologist to identify relevant areas making outcomes highly operatordependent.”
With VX1, Volta has developed the first commercially available companion AI decision support software to assist operators in the real-time annotation of 3D anatomical and electrical maps of human atria for the presence of multipolar intra-cardiac atrial abnormal EGMs during atrial fibrillation or atrial tachycardia. The cutting-edge software solution uses machine learning including deep learning algorithms to detect abnormal signals and thus highlights potential regions of interest during AF ablation procedures. The system works in real time and identifies specific abnormal EGMs, known as dispersed EGMs. Théophile Mohr Durdez, CEO and Co-Founder of Volta Medical, added: “The publication of these peer-reviewed trial results provides further validation of our approach – to leverage AI with cutting-edge software solutions and assist operators during cardiac ablation procedures. Over 1000 procedures have so far been supported in the EU and US by VX1 and based on clinician’s feedback and clinical results, we are confident that this approach will ultimately contribute to make ablation outcomes significantly more reliable.”
Based on these encouraging results, Volta Medical has initiated the TAILORED-AF trial, the first randomized controlled clinical trial to evaluate VX1-guided ablation compared to a ‘standard of care’ anatomical ablation approach. The aim of the study is to confirm the clinical significance of Volta Medical’s technology and lay the ground for establishing VX1 as a new standard of care for persistent AF ablation.
“The results of the Ev-AIFib trial show that Volta’s AI enhanced VX1 software is finally able to provide reliability and reproducibility in an EGM based approach – the holy grail of EGM based ablation approaches. The technology has shown a high potential to assist in treating the complex persistent AF patients,” said Prof. Dr. Isabel Deisenhofer, MD, head of electrophysiology at German Heart Centre Munich, and principial investigator of the international, multicenter TAILORED-AF trial. She continues: “In my experience, VX1 has been an extremely helpful tool, and I look forward to further explore and confirm the technology’s potential in the ongoing TAILORED-AF trial.”
About Ev-AIFib Trial
The EV-AIFib trial, a prospective, multicenter, non-randomized, study was designed to determine the feasibility and relevance of constructing standardized dispersion maps, so called ‘Volta VX1 maps’, to be used as a reference to operators conducting EGM-guided ablation of patients in persistent atrial fibrillation (AF), as well as the use of the VX1 technology for center-to-center standardization of dispersion mapping. In the trial physicians were provided with VX1 adjudications in real time and used their discretion to ablate where it was the most clinically relevant. Carried out in 8 different centers with 17 participating operators, the study compared the acute and long-term outcomes of 85 patients after ablation in regions exhibiting dispersion between a primary and satellite centers. At the primary center, operators were the most experienced at dispersion-based ablation, while satellite centers corresponded to hospitals where physicians had little experience at performing dispersion-based ablation. The results were also compared to a control group in which dispersion-guided ablation was performed visually by trained operators.
About Atrial Fibrillation (AF)
AF can be considered an “electrical storm” in the atria in which all synchronized activities have disappeared, and the necessary coordination of the contraction stops. This can lead to a number of symptoms including palpitations, shortness of breath and in some patients, heart failure.
AF affects approximately 33 million patients worldwide – a figure expected to double by 2030 driven by an aging population.1 Evidence suggests a higher prevalence of AF in patients with hypertension, heart failure, coronary heart disease, obesity and diabetes. In addition, recent studies show that 20-30% of patients with ischemic stroke have had AF before, during or after the initial event. AF is also a major risk factor for stroke, increasing the likelihood of stroke by four to five times, as stagnant blood in the atrium during AF may lead to the formation of a clot, which can migrate to the brain. In addition, AF-induced strokes are associated with more severe damage.
Common treatment for AF includes medication that regulates or slows the heart rate.2 For patients who cannot tolerate or who are resistant to anti-arrhythmic drug therapy, ablation is the current standard of care.2 Ablation uses heat or cold energy to create tiny scars in the heart to block abnormal electrical signals and restore a normal heartbeat.1 However, the efficacy of this approach depends to a large degree on the experience and intuition of the ablating physician.
About the Volta VX1 AI decision support software
VX1 consists of a highly innovative AI algorithm that is compatible with most readily available multipolar catheters and mapping technologies currently used in operating rooms or electrophysiology labs. VX1 is a medical device which is FDA cleared and has a CE mark. The FDA label reads “The VX1 assists operators in the real-time annotation of 3D anatomical and electrical maps of human atria for the presence of multipolar intra-cardiac atrial EGMs exhibiting specific abnormal EGM, known as dispersion, during atrial fibrillation or atrial tachycardia. The clinical significance of utilizing the VX1 software to help identify areas with intra-cardiac atrial EGMs exhibiting spatiotemporal dispersion for catheter ablation of atrial arrhythmias, such as atrial fibrillation, has not been established by clinical investigations.”
About Volta Medical
Founded by three physicians and a data scientist in 2016 in Marseille, Volta Medical is a health tech company developing artificial intelligence software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures. Volta’s overarching goal is to drastically improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection. Its first product, VX1, a digital AI companion device and algorithm assists cardiologists for the real-time identification of specific abnormal EGMs, known as dispersed EGMs.
For more information, visit the company’s website at www.volta-medical.com.
Media Contacts
Volta Medical
Jeff Martin, VP of Global Marketing
jeffrey.martin@volta-medical.com
U.S. Media Contact
FinnPartners
Glenn Silver
glenn.silver@finnpartners.com
Europe Media Contact
MC Services AG
Julia Bittner
julia.bittner@mc-services.eu
France Media Contact
Alize RP
Caroline Carmagnol
caroline@alizerp.com
References
1 Chugh SS, Havmoeller R, Narayannan K, et al. Worldwide epidemiology of atrial fibrillation: A global burden of
disease 2010 study. Circulation 2014; 129:837–8472
2 Mayo Clinic, Patient Care & Health Information, Tests & Procedures, Cardiac Ablation:
https://www.mayoclinic.org/tests-procedures/cardiac-ablation/about/pac-20384993

Looking for new talents
Volta Medical brings together a team of top-talent dedicated to make a difference in the field of interventional cardiac electrophysiology.
Volta’s collaborators come from multiple countries and continents.
Our headquarters are located in Marseille. Marseille is in the South of France, on the Mediterranean sea. This creates a unique atmosphere, particularly prone to creativity and collaboration.
At Volta, we are convinced that everyone of us may contribute to improving the lives of patients with cardiac arrhythmias. This is what drives us to come to work every single day. Many of us also enjoy the natural scene and conviviality in Marseille. You may find us celebrating milestones nearby (or on!) the Mediterranean sea.
If you are inspired, feel free to reach out! We would love to review your application.

Science

ABOUT Atrial Fibrillation
The heart beats are generated by the sino-atrial node, a small tissue region in the right atrium. The propagation of impulses to both upper chambers of the heart – i.e the two atria – causes them to contract and move the blood to the lower chambers of the heart, a.k.a the ventricles.
Atrial fibrillation (AF) is the most common heart rhythm disturbance in adults. AF is caused by abnormal electrical impulses forming anywhere in the atria. AF may be recorded on an electrocardiogram (ECG). The beating heart of AF patients is fast and irregular.
Physicians classify AF according to the duration of arrhythmia episodes. Brief episodes correspond to paroxysmal AF. Longer episodes are known as persistent AF.

ABOUT Interventional electrophysiology
Interventional electrophysiology is a surgical specialty. It requires multiple years of experience and consists of conducting intra-cardiac procedures to cure cardiac arrhythmias such as atrial fibrillation.
During an intervention, an electrophysiologist is required to analyze a large amount of information in real-time. First, an accurate visual analysis of up to 30 electrograms is essential. Then, non-electrogram information coming from multiple sources needs additional consideration.
All data allow for seamless progress through the multiple-step procedural workflow.